A new strategy for solid tumor treatment: the immunotherapeutic potential of chimeric antigen receptor macrophages

Electronic Journal of Liver Tumor ›› 2024, Vol. 11 ›› Issue (3): 16-19.

Previous Articles Next Articles

A new strategy for solid tumor treatment: the immunotherapeutic potential of chimeric antigen receptor macrophages

Kong Qinghao^1,2, Li Shuang^2,3, Lu Yinying^2,*

1. The Second Clinical Medical College of Anhui Medical University, Hefei 230022, Anhui, China;
2. Department of Liver Diseases, The Fifth Medical Center of Chinese People's Liberation Army General Hospital, Beijing 100039, China;
3. Peking University 302 Clinical Medical School, Beijing 100039, China

Received:2024-06-27 Online:2024-09-30 Published:2024-11-21
Contact: ^*Lu Yinying, Email: luyinying1973@163.com

Abstract

Abstract: Solid tumors are one of the major diseases threatening human health worldwide. Traditional treatments such as surgery, radiotherapy, and chemotherapy have their inherent limitations, and although immune checkpoint inhibitors have shown efficacy, not all patients respond to them. Chimeric antigen receptor-macrophage (CAR-M) therapy involves the genetic engineering of macrophages to express chimeric receptors that specifically recognize tumor antigens, demonstrating the potential for targeted tumor cell destruction. However, CAR-M therapy for solid tumors is currently in the preclinical and early clinical research stages. This paper provides a comprehensive review of the current state of preclinical studies on CAR-M, including the design of CAR structures, sources of donor cells, and vectors for delivering CAR genes to macrophages. Additionally, it summarizes the limitations and challenges faced in the development of CAR-M, offering new research perspectives for the future advancement of CAR-M therapy.

Key words: Chimeric antigen receptor, Macrophage, Tumor-associated macrophage, Solid tumor

Kong Qinghao, Li Shuang, Lu Yinying. A new strategy for solid tumor treatment: the immunotherapeutic potential of chimeric antigen receptor macrophages[J]. Electronic Journal of Liver Tumor, 2024, 11(3): 16-19.

References

[1] RAMOS-CASALS M, BRAHMER J R, CALLAHAN M K, et al.Immune-related adverse events of checkpoint inhibitors[J]. Nat Rev Dis Primers, 2020, 6(1): 38.
[2] DAS S, JOHNSON D B.Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors[J]. J Immunother Cancer, 2019, 7(1): 306.
[3] CHEN Y, YU Z, TAN X, et al.CAR-macrophage: a new immunotherapy candidate against solid tumors[J]. Biomed Pharmacother, 2021, 139: 111605.
[4] ANDERSON N R, MINUTOLO N G, GILL S, et al.Macrophage-based approaches for cancer immunotherapy[J]. Cancer Res, 2021, 81(5): 1201-1208.
[5] KIM J, BAE J S.Tumor-associated macrophages and neutrophils in tumor microenvironment[J]. Mediators Inflamm, 2016: 6058147.
[6] PAN K, FARRUKH H, CHITTEPU V, et al.CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy[J]. J Exp Clin Cancer Res, 2022, 41(1): 119.
[7] LOCATI M, CURTALE G, MANTOVANI A.Diversity, mechanisms, and significance of macrophage plasticity[J]. Annu Rev Pathol, 2020, 15: 123-147.
[8] WAGNER J, RAPSOMANIKI M A, CHEVRIER S, et al.A single-cell atlas of the tumor and immune ecosystem of human breast cancer[J]. Nat Genet, 2021, 53(9): 1334-1347.
[9] QIAN B Z, POLLARD J W.Macrophage diversity enhances tumor progression and metastasis[J]. Cell, 2010, 141(1): 39-51.
[10] ZHANG H, LIU L, LIU J, et al.Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers tumor-associated macrophages: an accomplice in solid tumor progression[J]. Mol Cancer, 2023, 22(1): 58.
[11] SLY L M, MCKAY D M.Macrophage immunotherapy: overcoming impediments to realize promise[J]. Trends Immunol, 2022, 43(12): 959-968.
[12] MAALEJ K M, MERHI M, INCHAKALODY V P, et al.CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances[J]. Mol Cancer, 2023, 22(1): 20.
[13] LIU Q, LI J, ZHENG H, et al.Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T[J]. Mol Cancer, 2023, 22(1): 28.
[14] BIGLARI A, SOUTHGATE T D, FAIRBAIRN L J, et al.Human monocytes expressing a CEA-specific chimeric CD64 receptor specifically target CEA-expressing tumour cells in vitro and in vivo[J]. Gene Ther, 2006, 13(7): 602-610.
[15] MORRISSEY M A, WILLIAMSON A P, STEINBACH A M, et al.Chimeric antigen receptors that trigger phagocytosis[J]. Elife, 2018, 7: e36688.
[16] KLICHINSKY M, RUELLA M, SHESTOVA O, et al.Human chimeric antigen receptor macrophages for cancer immunotherapy[J]. Nat Biotechnol, 2020, 38(8): 947-953.
[17] HYNES R O, NABA A.Overview of the matrisome--an inventory of extracellular matrix constituents and functions[J]. Cold Spring Harb Perspect Biol, 2012, 4(1): a004903.
[18] CASARI M, SIEGL D, DEPPERMANN C, et al.Macrophages and platelets in liver fibrosis and hepatocellular carcinoma[J]. Front Immunol, 2023, 14: 1277808.
[19] ZHANG W, LIU L, SU H, et al.Chimeric antigen receptor macrophage therapy for breast tumours mediated by targeting the tumour extracellular matrix[J]. Br J Cancer, 2019, 121(10): 837-845.
[20] CERNECKIS J, CAI H, SHI Y.Induced pluripotent stem cells (iPSCs): molecular mechanisms of induction and applications[J]. Signal Transduct Target Ther, 2024, 9(1): 112.
[21] ZHANG L, TIAN L, DAI X, et al.Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions[J]. J Hematol Oncol, 2020, 13(1): 153.
[22] LEI A, YU H, LU S, et al.A second-generation M1-polarized CAR macrophage with antitumor efficacy[J]. Nat Immunol, 2024, 25(1): 102-116.
[23] KANG M, LEE S H, KWON M, et al.Nanocomplex-mediated in vivo programming to chimeric antigen receptor-M1 macrophages for cancer therapy[J]. Adv Mater, 2021, 33(43): e2103258.
[24] GENTEK R, MOLAWI K, SIEWEKE M H.Tissue macrophage identity and self-renewal[J]. Immunol Rev, 2014, 262(1): 56-73.

A new strategy for solid tumor treatment: the immunotherapeutic potential of chimeric antigen receptor macrophages

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 0

Recommended Articles

Metrics

Comments